Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency

A technology for the sequelae of cerebral hemorrhage and cardiac insufficiency, applied in the field of medicine, can solve the problems of not being able to exert the drug effect quickly, alleviating the symptoms of chronic patients, and low bioavailability, so as to improve the bioavailability, the curative effect and the bioavailability high effect

Inactive Publication Date: 2017-10-10
广西大海阳光药业有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention aims at the problems of long disintegration time, low dissolution rate, poor absorption and low bioavailability in the existing adenosine triphosphate disodium tablets, which cannot quickly exert the drug effect and quickly alleviate the symptoms of chronic patients, etc., and provides a disintegration Fast speed, good dissolution, high dispersion, easy absorption, high bioavailability, fast onset, convenient to take pharmaceutical preparations for the treatment of progressive muscular atrophy, sequelae of cerebral hemorrhage, cardiac insufficiency and its preparation method, which solves the current market problems. The above-mentioned problems existing in the disodium adenosine triphosphate tablet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency
  • Pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency
  • Pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] A method for preparing a dispersible tablet from a pharmaceutical preparation for treating progressive muscular atrophy, sequelae of cerebral hemorrhage, and cardiac insufficiency, comprising the following steps:

[0066] T1: Weigh the following components by weight: Adenosine triphosphate disodium 10000g, sodium alginate 20000g, hydroxypropyl methylcellulose 10000g, dextran 40000g, carboxymethyl starch sodium 5000g, sodium lauryl sulfate 5000g, Micropowder silica gel 1500g, magnesium stearate 1500g, pass through a 100-mesh sieve, set aside;

[0067] T2: Preparation of disodium adenosine triphosphate inclusion compound: take weighed sodium alginate and put it in the batching tank, add 60000g of water and heat to 45°C to make the swelling complete, keep the temperature at 45°C and slowly add disodium adenosine triphosphate, keep warm Stir for 2 hours, let it cool to room temperature, take it out, dry it at -0.06Mpa vacuum degree of drying temperature at 50°C for 12 hours...

Embodiment 2

[0074] A method for preparing a dispersible tablet from a pharmaceutical preparation for treating progressive muscular atrophy, sequelae of cerebral hemorrhage, and cardiac insufficiency, comprising the following steps:

[0075] T1: Weigh the following components by weight: adenosine triphosphate disodium 10000g, sodium alginate 40000g, hydroxypropyl methylcellulose 20000g, dextran 80000g, sodium carboxymethyl starch 20000g, sodium lauryl sulfate 10000g, Micropowder silica gel 3000g, magnesium stearate 3000g, pass through a 100-mesh sieve, set aside;

[0076] T2: Preparation of disodium adenosine triphosphate inclusion compound: take weighed sodium alginate and put it in the batching tank, add 80,000g of water and heat to 65°C to make the swelling complete, keep the temperature at 65°C and slowly add disodium adenosine triphosphate, keep warm Stir for 1 hour, let it cool to room temperature, take it out, dry at -0.09Mpa vacuum degree of drying temperature 65°C for 8 hours, pul...

Embodiment 3

[0083] A method for preparing a dispersible tablet from a pharmaceutical preparation for treating progressive muscular atrophy, sequelae of cerebral hemorrhage, and cardiac insufficiency, comprising the following steps:

[0084] T1: Weigh the following components by weight: adenosine triphosphate disodium 10000g, sodium alginate 30000g, hydroxypropyl methylcellulose 15000g, dextran 60000g, carboxymethyl starch sodium 10000g, sodium lauryl sulfate 7500g, Micropowder silica gel 2000g, magnesium stearate 2000g, pass through a 100-mesh sieve, set aside;

[0085] T2: Preparation of disodium adenosine triphosphate inclusion compound: take weighed sodium alginate and put it in the batching tank, add 70000g of water and heat to 55°C to make the swelling complete, keep the temperature at 55°C and slowly add disodium adenosine triphosphate, keep warm Stir for 1.5h, let it cool to room temperature, take it out, dry at -0.07Mpa vacuum degree of drying temperature 60°C for 10h, pulverize, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency, and a preparation method thereof. The pharmaceutical preparation for treating progressive muscular atrophy, cerebral hemorrhage sequelae and cardiac insufficiency is prepared from the following components in parts by weight: 100 parts of adenosine disodium triphosphate, 200-400 parts of sodium alginate, 100-200 parts of hydroxypropyl methylcellulose, 400-800 parts of glucan, 50-200 parts of sodium carboxymethyl starch, 50-100 parts of sodium dodecyl sulfate, 15-30 parts of a micropowder silica gel and 15-30 parts of magnesium stearate. According to the preparation method disclosed by the invention, the adenosine disodium triphosphate is prepared into an inclusion compound by a sodium alginate swelling technique, and then the main drug inclusion compound is further prepared into dispersible tablets. The adenosine disodium triphosphate in the product disclosed by the invention has increased dissolubility, higher dissolution rate, shortened disintegration time limited and improved bioavailability, thereby improving the curative effect, and the preparation method has simple process, low production cost, low energy consumption and easy implementation of industrialized production.

Description

technical field [0001] The invention belongs to the field of pharmaceuticals, and relates to a pharmaceutical preparation and a preparation method thereof, in particular to a pharmaceutical preparation for treating progressive muscular atrophy, sequelae of cerebral hemorrhage, and cardiac insufficiency and a preparation method thereof. Background technique [0002] Adenosine triphosphate (ATP), a coenzyme. Adenosine triphosphate disodium is a nucleotide derivative and a high-energy substance produced by the body itself. It is the center of energy utilization and storage in the body and participates in the metabolism of fat, protein, sugar, nucleic acid and nucleotide in the body. When energy is needed for absorption, secretion, muscle contraction and biochemical synthesis reactions in the body, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time, which plays an extremely important role in life activiti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/7076A61K47/32A61K47/36A61K47/20A61K47/38A61K47/04A61K47/12A61P21/00A61P25/00A61P9/04A61P9/06A61P9/10A61P31/14A61P9/00
CPCA61K31/7076A61K9/0056A61K9/2009A61K9/2013A61K9/2027A61K9/205A61K9/2054A61K9/2059
Inventor 黄大权唐新
Owner 广西大海阳光药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com